Differences between developed and developing countries in paediatric care in haemophilia

被引：17

作者：

De Kleijn, P. ^{[8
]}

Odent, T. ^{[1
]}

Berntorp, E. ^{[2
]}

Hilliard, P. ^{[3
]}

Pasta, G. ^{[4
]}

Srivastava, A. ^{[5
]}

Iliescu, A. ^{[6
]}

Mohanty, S. ^{[7
]}

机构：

[1] Hop Enfants Malad Assistance Publ Hop Paris, Dept Orthopaed Surg, Paris, France

[2] Malmo Univ Hosp Malmo, Dept Coagulat Disorders, Malmo, Sweden

[3] Hosp Sick Children, Hematol Oncol Clin, Hemophilia Program, Toronto, ON M5G 1X8, Canada

[4] Haemophilia Ctr Angelo Bianchi Bonomi, Dept Orthoped, Milan, Italy

[5] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India

[6] Romania Hemophilia Assoc, Timisoara, Romania

[7] King Edward Mem Hosp, Bombay, Maharashtra, India

[8] UMC, Utrecht, Netherlands

来源：

HAEMOPHILIA | 2012年 / 18卷

关键词：

hemophilia; orthopedic surgery; pediatric care; prophylactic treatment; rehabilitation; ARTHROSCOPIC SYNOVECTOMY; PROPHYLACTIC TREATMENT; JOINT DISEASE; MANAGEMENT; COMPLICATIONS; HEMARTHROSIS; ARTHROPATHY; POPULATION; INHIBITORS; WORLD;

D O I：

10.1111/j.1365-2516.2012.02875.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

. The aim of this article is to provide an up-to-date overview on paediatric haemophilia care in the world, with emphasis on medical treatment, rehabilitation, and orthopaedic surgery. The reason these specific professions caregivers are included is that over 90% of bleeding episodes in people with haemophilia (PWH) occur within the musculoskeletal system; and of these 80% of bleedings occur in joints.

引用

页码：94 / 100

页数：7

共 47 条

[11] Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study [J].

Feldman, BM ;

Pai, M ;

Rivard, GE ;

Israels, S ;

Poon, MC ;

Demers, C ;

Robinson, S ;

Luke, KH ;

Wu, JKM ;

Gill, K ;

Lillicrap, D ;

Babyn, P ;

McLimont, M ;

Blanchette, VS .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (06) :1228-1236

[12] Chemical synoviorthesis with oxytetracycline clorhydrate (Emicine®) in recurrent haemarthrosis [J].

Fernandez-Palazzi, F. ;

Cedeno, M. ;

Maldonado, J. C. ;

Boadas, A. ;

De Saez, A. R. ;

Chacal B., F. ;

De Bosch, N. B. .

HAEMOPHILIA, 2008, 14 (01) :21-24

[13] Anti-inflammatory effects of continuous passive motion on meniscal fibrocartilage [J].

Ferretti, M ;

Srinivasan, A ;

Deschner, J ;

Gassner, R ;

Baliko, F ;

Piesco, N ;

Salter, R ;

Agarwal, S .

JOURNAL OF ORTHOPAEDIC RESEARCH, 2005, 23 (05) :1165-1171

[14] Dose and outcome of care in haemophilia - how do we define cost-effectiveness? [J].

Fischer, K ;

Van den Berg, HM ;

Thomas, R ;

Kumar, S ;

Poonnoose, P ;

Viswabandya, A ;

Mathews, V ;

Kavitha, ML ;

Bhattacharji, S ;

Srivastava, A .

HAEMOPHILIA, 2004, 10 :216-220

[15] Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen [J].

Fischer, K ;

Astermark, J ;

Van der Bom, JG ;

Ljung, R ;

Berntorp, E ;

Grobbee, DE ;

Van den Berg, HM .

HAEMOPHILIA, 2002, 8 (06) :753-760

[16]

Fischer K, 2001, HAEMOPHILIA, V7, P21

[17] Epsilon-aminocaproic acid inhibits the activity of factor VIII inhibitors in patients with severe haemophilia A in vivo and in vitro [J].

Ghosh, K ;

Shetty, S ;

Pathare, A ;

Mohanty, D .

ACTA HAEMATOLOGICA, 2000, 103 (02) :67-72

[18] Management of haemophilia and its complications in developing countries [J].

Ghosh, K .

CLINICAL AND LABORATORY HAEMATOLOGY, 2004, 26 (04) :243-251

[19]

Ghosh K, 1999, HAEMOPHILIA, V5, P364

[20] HEMOPHILIA IN THE 1990S - PRINCIPLES OF MANAGEMENT AND IMPROVED ACCESS TO CARE [J].

KASPER, CK ;

MANNUCCI, PM ;

BULYZHENKOV, V ;

BRETTLER, DB ;

CHUANSUMRIT, A ;

HEIJNEN, L ;

ISARANKURA, P ;

KERNOFF, PBA ;

PEAKE, I ;

RICKARD, KA ;

SCHULMAN, S ;

SIBINGA, CTS .

SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1992, 18 (01) :1-10

← 1 2 3 4 5 →